camptothecin has been researched along with i(3)so3-galactosylceramide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colman, H; Conrad, CA; Emmett, MR; He, H; Ji, Y; Kroes, RA; Lang, FF; Marshall, AG; Moskal, JR; Nilsson, CL | 1 |
1 other study(ies) available for camptothecin and i(3)so3-galactosylceramide
| Article | Year |
|---|---|
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
Topics: Animals; Camptothecin; Cell Line, Tumor; Gangliosides; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Glioma; Glycomics; Humans; Irinotecan; Lipids; Mice; Phosphatidylglycerols; Sulfoglycosphingolipids; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2010 |